Sanofi acquired rilzabrutinib as part of the $3.68bn acquisition of Principia in 2020. Image Credit: Keitma / Shutterstock.

Sanofi shared positive results from the Phase II trial of rilzabrutinib in patients with moderate to severe chronic spontaneous urticaria (CSU).

The Phase II RILECSU study (NCT05107115) showed an improvement in CSU symptoms such as itching, hives and urticaria in CSU patients whose symptoms are inadequately controlled by H1-antihistamines.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The RILECSU trial formed the basis of the Phase III study, which is expected to start later this year.

Rilzabrutinib is a Burton tyrosine kinase (BTK) inhibitor acquired by Sanofi in 2020 as part of its $3.68bn acquisition of Principia. The drug has yet to show positive results in late-stage clinical trials. In 2021, rilzabrutinib failed to show improvement in the Phase III trial (NCT03762265) as a treatment for a rare autoimmune skin disease, pemphigus.

The drug also failed to meet the eczema area and severity endpoint in the Phase II atopic dermatitis trial (NCT05018806). Sanofi noted that “numerical improvements were seen in other important clinical components” of atopic dermatitis.

The RILECSU trial met its primary endpoint by demonstrating a reduction in weekly itch severity score (ISS7) and weekly urticaria activity score (UAS7) at 12 weeks compared to baseline. Patients in the rilzabrutinib group also showed a reduction in weekly hives severity score (HSS7) at 12 weeks compared to the baseline. The treatment-emergent adverse effects included diarrhoea, nausea, headache, and abdominal pain.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Chronic spontaneous urticaria, also known as chronic hives, is a skin condition that causes red, raised, and itchy hives that are occasionally painful. The hives last for six weeks or more and are managed symptomatically with antihistamines, antipruritic, and anti-inflammatories.

Sanofi also has another CSU therapy in its portfolio, Dupixent (dupilumab). The blockbuster therapy was developed in partnership with Regeneron. This month, it was approved as a treatment for CSU in patients aged 12 years and older by the Japanese Ministry of Health, Labor and Welfare

Sanofi is also evaluating rilzabrutinib in multiple autoimmune indications, including a Phase III trial (NCT04562766) for heavily pre-treated immune thrombocytopenia and Phase II trials in warm autoimmune haemolytic anaemia (NCT05002777), IgG4-related disease (NCT04520451), and moderate to severe asthma (NCT05104892). The readouts from the Phase II trials are expected this year.